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The purpose of this study was to evaluate the difference in dose-volumetric data 
between the analytical anisotropic algorithms (AAA) and the two dose reporting 
modes of the Acuros XB, namely, the dose to water (AXB_Dw) and dose to medium 
(AXB_Dm) in lung stereotactic body radiotherapy (SBRT). Thirty-eight plans were 
generated using the AXB_Dm in Eclipse Treatment Planning System (TPS) and 
then recalculated with the AXB_Dw and AAA, using identical beam setup. A dose 
of 50 Gy in 4 fractions was prescribed to the isocenter and the planning target 
volume (PTV) D95%. The isocenter was always inside the PTV. The following 
dose-volumetric parameters were evaluated; D2%, D50%, D95%, and D98% for 
the internal target volume (ITV) and the PTV. Two-tailed paired Student’s t-tests 
determined the statistical significance. Although for most of the parameters evalu-
ated, the mean differences observed between the AAA, AXB_Dm, and AXB_Dw 
were statistically significant (p < 0.05), absolute differences were rather small, in 
general less than 5% points. The maximum mean difference was observed in the ITV 
D50% between the AXB_Dm and the AAA and was 1.7% points under the isocenter 
prescription and 3.3% points under the D95 prescription. AXB_Dm produced higher 
values than AXB_Dw with differences ranging from 0.4 to 1.1% points under iso-
center prescription and 0.0 to 0.7% points under the PTV D95% prescription. The 
differences observed under the PTV D95% prescription were larger compared to 
those observed for the isocenter prescription between AXB_Dm and AAA, AXB_Dm 
and AXB_Dw, and AXB_Dw and AAA. Although statistically significant, the mean 
differences between the three algorithms are within 3.3% points. 
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The field of radiation oncology has rapidly evolved over the last three decades due to the 
advances in diagnostic radiology that allows for better tumor volume definition during treat-
ment planning, and the development of new irradiation techniques such as intensity-modulated 
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radiotherapy (IMRT) and stereotactic body radiation therapy (SBRT), making possible a 
better optimization of dose distribution around the planning target volume (PTV).(1) Those 
advanced techniques require a high and verified accuracy in dose calculation to ensure that the 
prescribed dose is actually delivered to the tumor with good sparing of the surrounding normal 
tissues. This would result in an increased cure rates, as well as improved patients’ tolerance to 
treatment.(2) Indeed, according to the American Association of Physicists in Medicine (AAPM) 
Report No. 85, a 5% change in dose may induce a 10% to 20% change in tumor control prob-
ability (TCP) and a 20% to 30% change in complication rates of normal tissues (NTCP).(3) 
Due to the high dose and small number of fractions used in SBRT, accuracy issue becomes of 
even greater importance.(4)
Monte Carlo (MC) dose calculation algorithm, which stochastically solves the Linear 
Boltzmann Transportation Equations (LBTE), is considered as the gold standard in terms of 
accuracy, especially in heterogeneous media such as lung.(5) MC explicitly models the physical 
interaction of each particle in media, a process which remains time-consuming despite recent 
advances in computing power. This explains why MC is still not widely used in daily clinical 
practice.(5,6) Recently, another dose calculation algorithm using a deterministic grid-based 
Boltzmann equation solver has been licensed by Varian Medical Systems (Palo Alto, CA) and 
has been implemented in the Eclipse Treatment Planning System as the Acuros XB (AXB), 
advanced dose calculation algorithm.(7) AXB has shown to agree very well with MC, even in 
heterogeneous media, with the advantage of having a faster calculation times and being avail-
able on a commercial TPS.(8,9) 
Like MC, AXB can report the absorbed dose in two modes: dose-to-water (Dw) and dose-to-
medium (Dm). The Dw has been widely used in conventional radiotherapy and several dosimetry 
protocols are based on Dw. However, recent trends are in the use of LBTE solver type algo-
rithms, which can report dose to medium in addition to Dw. It should be noted however that, 
although the question of which dose reporting mode to use remains controversial,(10) Dm can be 
rescaled to Dw using the stopping-power ratio of water-to-medium. Siebers et al.
(11) evaluated 
water-to-medium mass collision stopping-power ratios as a function of electron energy. They 
reported a substantial decrease in the water-to-medium stopping power for the lung with an 
increase in the monoenergetic electron energy, suggesting that the difference between Dm and 
Dw may increase in favor of the Dw when it comes to the lung.
Recently several studies have compared the dose-volumetric data obtained with AXB_Dm, 
with either MC or the analytical anisotropic algorithm (AAA), but only a few studies have 
evaluated the difference in dose-volumetric data between the two dose reporting modes of 
AXB in lung cancer patients treated with SBRT8.(12–18) Rana and Pokharel(16) reported that 
the selection of either Dm or Dw in AXB is less likely to produce significant dosimetric dif-
ferences in the clinical environment. However, only five patients in their series were treated 
with SBRT for lung cancer, making it difficult to draw any conclusion from their study. The 
aim of the present study is to evaluate the difference in dose-volumetric parameters between 
the AXB_Dm and AXB_Dw on a larger series of clinical patients treated with SBRT for lung 
cancer. Additionally, we also compared the dose-volumetric data of either dose reporting mode 
of the AXB with the AAA. 
 
II. MATERIALS AND METHODS
A.  Treatment procedure 
All patients underwent a respiration-correlated 4D CT scan using the Varian Real Time Position 
Management Respiratory Gating System, version 1.7 (Varian Medical Systems) and a Discovery 
CT750HD CT Scanner (General Electric Medical Systems, Waukesha, WI) with a slice thick-
ness of 2.5 mm in the axial cine mode.
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Then, the 4D CT slices and respiratory motion data were transferred to an Advantage 4D 
Workstation (General Electric Medical Systems, San Francisco, CA), where maximum inten-
sity projection (MIP) and averaged intensity projection (AIP) images were obtained after a 
phase binning of the 4D CT in 10 equally spaced phase bins. The dataset was imported to the 
Eclipse (Varian Medical Systems) for treatment planning using 6 MV photon beams. ITV was 
delineated on the AIP image with references to the MIP image. PTVs were created by adding 
5-mm margins to the ITVs in all directions.(19) A dose of 50 Gy in 4 fractions was prescribed to 
the isocenter and the PTV D95%. The isocenter was always inside the PTV. Dose calculation 
was done with the default dose-to-medium reporting mode of the AXB (version 11.0.31) with 
a grid size of 2.5 × 2.5 × 2.5 mm3. Recalculation was subsequently done with the AXB_Dw 
and AAA (version 11.0.31) using identical beam setup.
B.  Evaluated parameters
The dose received by n% volume of the target volume (ITV and PTV), D2%, D50%, D95%, 
and D98%, were evaluated. We compared the relative differences in the corresponding evalu-
ated parameters between AXB_Dm and AAA, AXB_Dm and AXB_Dw, and AXB_Dm and AAA. 
The two-sided, paired Student’s t-test was used to determine the statistical significance. Values 
of p < 0.05 were regarded as significant. 
 
III. RESULTS 
Thirty-seven consecutive patients diagnosed with lung cancer and treated with SBRT from 
July 2011 to August 2015 were included in the present dosimetric study. One patient had 
two lesions, one in the right and one in left lung. In total, 38 treatment plans were developed. 
Table 1 summarized the dose-volumetric data results under the isocenter and the PTV D95% 
prescription for all the 37 patients. 
Table 1.Dose-volumetric data calculated with AXB_Dm, AXB_Dw, and AAA. Data are shown as mean ± standard 
deviation.
 Isocenter PTV D95%
 (%) (%)
  AXB_Dm AXB_Dw AAA AXB_Dm AXB_Dw AAA
PTV
 D2%e 101.7±2.2 101.0±2.1 100.6±1.7 133.4±7.7 133.1±7.6 131±6.5
 D50%a 95.4±4.0 94.8±3.5 93.9±3.2 120.4±4.3 120.3±4.3 118±4.3
 D95%d 86.9±6.2 86.5±6.0 86.2±5.5 100.1±0.0 100.1±0.0 100.1±0.0
 D98%c 84.6±7.0 84.2±6.8 84.2±6.5 93.8±2.4 93.8±2.4 94.2±2.6
ITV
 D2%b 102.1±1.9 101.1±1.6 101±1.3 134.3±8.2 133.9±8.2 132.1±7.1
 D50%a 98.6±2.2 97.7±1.8 96.9±1.9 128.3±7.4 127.6±7.3 125.0±6.4
 D95%a 94.0±3.4 93.3±3.3 92.4±3.2 118.5±12.5 118.2±12.5 115.9±12.1
 D98%a 92.7±5.0 92±5.0 91.2±4.8 116.0±15.0 115.8±14.9 113.6±14.8
a A significant difference was found between AXB_Dm and AAA, AXB_Dm and AXB_Dw and AAA and AXB_Dw.b A significant difference was found between AXB_Dm and AAA, AXB_Dm and AXB_Dw and AAA and AXB_Dw 
only under the PTV D95% prescription.
c A significant difference was found between AXB_Dm and AAA and AAA and AXB_Dw under the PTV D95% 
prescription.
d A significant difference was found between AXB_Dm and AAA, AXB_Dm and AXB_Dw under the isocenter prescription.e A significant difference was found between AXB_Dm and AAA, AXB_Dm and AXB_Dw, and AAA and AXB_Dw 
under the isocenter prescription and AXB_Dw and AAA and AXB_Dw under the PTV D95% prescription.
AXB_Dm = Acuros XB dose-to-medium reporting mode; AXB_Dw = Acuros XB dose-to-water reporting mode; AAA = 
analytical anisotropic algorithm; PTV = planning target volume; ITV = internal target volume; D95% = prescription 
covering 95% of the target volume.
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A.  Under the isocenter prescription 
The maximum mean difference observed in the ITV D50% between the AXB_Dm and the AAA 
was only 1.7% points, although statistically significant (p < 0.05). The difference in the PTV 
D98% was not statistically significant between the three algorithms with p = 0.88, 0.05, and 0.11 
between AXB_Dm and AAA, AXB_Dm and AXB_Dw, and AXB_Dm and AAA, respectively.
B.  Under the PTV D95% prescription
The maximum mean difference, observed in the ITV D50% between the AXB_Dm and the 
AAA was only 3.3% points, although statistically significant (p < 0.05). The difference in the 
PTV D98% and D2% was not statistically significant between the AXB_Dm and AXB_Dw 
(p = 0.19 and 0.18, respectively). The PTV D95% didn’t differ between the three algorithms. 
Figure 1 shows dose distributions and DVH for the patient with the largest difference between 
the AXB_Dm and the AAA. The percentage of the PTV receiving more than 130% of the pre-
scribed dose with AXB_Dm was almost double of that with AAA. In this patient, difference in 
D2% and D50% were more than 8.6% and 8.5%, respectively.
 
IV. DISCUSSION
LBTE solver type algorithm such a MC and AXB allows the expression of radiation transport 
and energy deposition in patient representative media. The dose reporting mode can then either 
be Dm or Dw, the difference between the two in Acuros XB being the way dose is calculated. 
Indeed, when Dm is calculated, the energy-dependent response function is based on the material 
Fig. 1. Representative dose distributions calculated with (a) AAA and (b) AXB_Dm in the axial plane, and (c) the cor-
responding dose-volume histograms for the PTV. A dose of 50 Gy in 4 fractions was prescribed to the PTV D95%.
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properties of that voxel. When Dw is calculated, the energy-dependent fluence-to-dose response 
function is based on water.(20) 
The possibility, at first provided by Monte Carlo simulation, of reporting the dose as Dm, has 
become a subject of controversy in medical physics community. The pros and cons of using 
either of the dose reporting modes have been discussed in a point/counterpoint debates published 
in Medical Physics.(10) In favor of using the Dm is the arguments that a) converting Dm back to 
Dw requires a stopping power ratio, adding uncertainties and increasing MC calculation time; 
b) the clinical impact of switching from Dw to Dm is not expected to be significant; and c) use 
of Dm allows the establishment of more accurate dose delivery, and provides a closer relation-
ship between tissue response and dose. On the other hand, arguments favoring the use of Dw 
included the following: a) clinical experience is Dw-based; b) dosimetry protocols are Dw-based; 
c) the “medium” to report dose in is always a guess since accompanying 3D body composition 
analysis is often absent; and d) clinical prescription can be achieved with Dw-based IMRT.
In the present study, we evaluated the difference in dose-volumetric data between the AXB_
Dw, AXB_Dm, and the AAA in a larger series of clinical patients treated for lung cancer with 
SBRT. Although for most of the parameters evaluated the mean differences observed between 
the AAA, AXB_Dm, and AXB_Dw were statistically significant, absolute differences were rather 
small, in general less than 5% points. Under both isocenter and PTV D95% prescription, the 
largest difference observed was between AXB_Dm and AAA in the ITV D50%, followed by the 
ITV D95% and ITV D98%; that was, in the ITV margin. This can be explained by the difference 
in radiation transport modeling between the AAA and the AXB. Furthermore, while the AAA 
computes the transport and dose deposition using radiological and density scaling, reports the 
absorbed dose as if it were deposited in water, but for both options of AXB, calculated dose 
considers the elemental composition of the specific medium. Doses calculated using AXB_Dw 
were generated by converting the doses calculated by AXB_Dm with the stopping-power ratio 
for water to the specific medium. The mean difference for both the ITV D50% and the remaining 
parameters evaluated was higher between AXB_Dm and AAA than AXB_Dw and AAA. Siebers 
et al.(11) reported that the stopping power tends to become small with an increase in the energy 
so that at 6 MV, the energy used in the present study, one could have expected that Dw produce 
higher values than Dm. However, in our study, AXB_Dm produced higher values, and the mean 
differences between AXB_Dw and AXB_Dm showed a clear trend in favor of AXB_Dm. Hence 
the larger differences observed between AXB_Dm and AAA than AXB_Dw and AAA. 
Studies evaluating the difference in dose-volumetric data between the two dose reporting 
modes of the AXB in lung SBRT patients are scarce. Rana and Pokharel(16) evaluating five 
patients, found the difference between AXB_Dm and AXB_Dw to be patient-specific without a 
clear trend, ranging from -1.4% to 2.9%. They concluded that the selection of either AXB_Dm 
or AXB_Dw is less likely to produce significant dosimetric differences in the clinical environ-
ment. In our study, using a larger series of clinical patients, we could observe a clear trend in 
favor of AXB_Dm with differences ranging from 0.4 to 1.1% points under isocenter prescrip-
tion and 0.0 to 0.7% points under the PTV D95% prescription. This rather small difference 
could be explained by the fact that the electron transport is the same between AXB_Dm and 
AXB_Dw, and only the electron energy deposition interaction is different. Moreover, the AAPM 
Report No. 85(21) and the study from Dische et al.(22) both stated that tumor response and tissue 
morbidity could be compromised by deviation from the prescribed dose of 5% or more. Based 
on that, the difference observed in our study was not clinically significant agreeing with the 
conclusion of the Rana study.
The differences observed under the PTV D95% prescription were larger compared to those 
observed under the isocenter prescription between AXB_Dm and AAA, AXB_Dm and AXB_Dw, 
and AXB_Dw and AAA. This is probably due to the more important difference between algo-
rithms when it comes to the modeling of dose near the interfaces. Indeed, AAA approximates 
the effect of electron disequilibrium at and near the interfaces between media of different density 
by an empirical convolution along a ray line, resulting in the underestimation of the build-up 
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and build-down effects near interfaces in the presence of very low density media like air, while 
AXB, that shares the same multiple-source model as AAA but different dose calculation, has 
shown to better agree with measurements.(12,23)
 
V. CONCLUSIONS
Although statistically significant for most of the evaluated parameters, the mean difference 
between the Dw and the Dm reporting mode of the AXB in SBRT plans for lung cancer patients 
was within 5% points. Both dose reporting mode of the AXB seemed to agree well with the 
AAA, with the largest difference observed between the Dm and the AAA.
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